Innovus Pharmaceuticals Acquires Four branded Products from Boston Topicals
Innovus Pharmaceuticals, Inc., an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter and consumer care products to improve men’s and women’s health and respiratory diseases, announced that the Company has acquired four branded topical products from Boston Topicals, LLC, expanding its retail and e-commerce presence in the Company’s current highest revenue grossing category. Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases.
Dr. Damaj, President and CEO of Innovus Pharma said that they continue to bolster their product pipeline with clinically and commercially validated products that fit both, consumer channels as well as retail stores.
HealthiFeet was among the products acquired, has been a proven category leader in pilot programs in multiple retail stores
The products include the diabetic retail category flagship HealthiFeet®, a foot cream, with a published double-blind controlled trial shown to increase temperature and blood flow in feet of diabetic patients and formulated with the KNOSIS™ transdermal delivery system.
“HealthiFeet® is an excellent candidate for our Beyond Human® sales and marketing platform,” said Chris Stella, Vice President of Operations at Innovus Pharma. “We’ve seen tremendous success in this product category with Diabasens®, a leg and foot relief topical product, which may exceed approximately $4.5 million in annual revenue this year. We are currently projecting HealthiFeet® to become another leader in this space. It also fits well in retail stores where the product has proven to be a category leader with pilot runs at Walmart, CVS and Walgreens and with wholesalers such as McKesson and Cardinal, in which it has had over $1.6 million in cumulative sales.”